✦ LIBER ✦

The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review

✍ Scribed by Michael Brundage; Himu Lukka; Juanita Crook; Padraig Warde; Glenn Bauman; Charles Catton; Barbara R Markman; Manya Charette

Book ID: 119512460
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 118 KB
Volume: 64
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(02)00184-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Conformal radiotherapy with dose escalat

Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer: Abstracted from: Brundage M, Lukka H, Crook J, et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer—a systematic review. Radiother Oncol 2002; 64: 239–50.

✍ Eric M Horwitz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 64 KB

The Cancer of the Prostate Risk Assessme

The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy

✍ Krishnan, Vimal; Delouya, Guila; Bahary, Jean-Paul; Larrivée, Sandra; Taussky, D 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

43 oral A retrospective comparison of th

43 oral A retrospective comparison of the use of androgen deprivation among low and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 132 KB

1045 poster THE PROGNOSTIC VALUE OF EXPR

1045 poster THE PROGNOSTIC VALUE OF EXPRESSION OF HIF 1, VEGF-A AND EGFR IN PROSTATE CANCER FOR INTERMEDIATE-RISK PATIENT TREATED WITH RADIATION THERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY.

✍ Tille, J.C.; Weber, D.C.; Hammad, K.; Granger, P.; Egger, J.F.; Rubbia-Brandt, L 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 36 KB

708 Side effects of BCG in the treatment

708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years

✍ Brausi, M.; Oddens, J.; Sylvester, R.; Colette, S.; Gontero, P.; Bono, A.; Turke 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 70 KB

1694 SIDE EFFECTS OF BCG IN THE TREATMEN

1694 SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS

✍ Brausi, Maurizio; Oddens, Jorg; Sylvester, Richard; Bono, Aldo; Gontero, Paolo; 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 95 KB